(Q35977647)

11 August 2017

1 reference

title

Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism (English)

1 reference

11 August 2017

main subject

venous thromboembolism

1 reference

Sylvia Haas

1

1 reference

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

64 Suppl 1

1 reference

11 August 2017

page(s)

7-16

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464001-00003

11 August 2017

exact match

0 references

cites work

Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines

1 reference

12 December 2020

Characterization of in Vitro Biotransformation of New, Orally Active, Direct Thrombin Inhibitor Ximelagatran, an Amidoxime and Ester Prodrug

1 reference

12 December 2020

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

12 December 2020

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

1 reference

12 December 2020

Heparin-induced thrombocytopenia

1 reference

12 December 2020

Hirudins: antithrombin anticoagulants

1 reference

12 December 2020

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

1 reference

12 December 2020

Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

1 reference

12 December 2020

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

12 December 2020

Kinetics of the inhibition of thrombin by hirudin.

1 reference

12 December 2020

Experimental Proof for the Structure of a Thrombin-Inhibiting Heparin Molecule

1 reference

12 December 2020

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

1 reference

12 December 2020

Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes

1 reference

12 December 2020

Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).

1 reference

12 December 2020

The Long-Term Clinical Course of Acute Deep Venous Thrombosis

1 reference

12 December 2020

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review

1 reference

12 December 2020

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

1 reference

12 December 2020

Identification of regions of alpha-thrombin involved in its interaction with hirudin

1 reference

12 December 2020

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

1 reference

12 December 2020

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

12 December 2020

New anticoagulants: current status and future potential

1 reference

12 December 2020

Oral direct thrombin inhibitors in clinical development

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction

1 reference

12 December 2020

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

12 December 2020

Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group

1 reference

12 December 2020

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

1 reference

12 December 2020

Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity

1 reference

12 December 2020

Natural anticoagulant mechanisms

1 reference

12 December 2020

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

1 reference

12 December 2020

10.2165/00003495-200464001-00003

Identifiers

DOI

0 references

Dimensions Publication ID

1051651962

0 references

1 reference